Lead Product(s): Ketamine analogs
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Deal Size: $15.7 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 07, 2020
Adelia’s leadership team brings deep clinical and commercialization experience, including past commercial success in psychedelics through the development of proprietary ketamine analogs as well as strong understanding of the underlying science.